Compare Novo Nordisk A/S (NVO) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Prudential PLC — how do they compare? Novo Nordisk A/S trades at $38.63 (market cap $165.31B), while Prudential PLC trades at $23.92 (market cap $28.84B). The key difference: Novo Nordisk A/S is far larger — about 5.7× Prudential PLC's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Prudential PLC for 119 Days on average.
| NVO | PUK | |
|---|---|---|
Market Cap | $165.31B | $28.84B |
Volume | 11,432,838 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $63.98 | $33.61 |
52-Week Low | $35.29 | $23.54 |
Typical Hold Time | 116 Days | 119 Days |
Enterprise Value | $179.56B | $28.38B |
Dividend Yield | 4.71% | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Prudential Public Limited Company (PUK) trades at $23.92, up 1.61% over 24 hours, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong revenue growth to $27.39B in 2025 and a net income of $3.98B, with improving profitability margins and a low P/E of 8.4. Recent news highlights strategic shifts, including the sale of its Alexforbes stake and a focus on core markets.
The outlook is mixed: solid fundamentals and analyst 'Moderate Buy' consensus support upside, but technical weakness and earnings misses pose near-term risks. Key opportunities include capital return initiatives and cost savings; risks involve execution of strategic overhaul and emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
